Skip to main content
SpringerLink
Log in

Kastrationsresistentes Prostatakarzinom

Notwendigkeit neuer Begrifflichkeiten

  • Medizin aktuell
  • Der wunde Punkt
  • Published:
Uro-News Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

© Holger Erb

Literatur

  1. Leitlinienprogramm Onkologie: Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.1, 2019, AWMF Registernummer: 043/022OL

  2. Scher HI et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-59

  3. Gaya, J.M., et al., Current, new and novel therapy for castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2013; 13: 819-27

  4. Akamatsu S et al. Clinical and molecular features of treatment-related neuroendocrine prostate cancer. Int J Urol. 2018; 25: 345-51

  5. Santer FR et al. Therapy escape mechanisms in the malignant prostate. Semin Cancer Biol. 2015; 35: 133-44

  6. Sharma AP et al. STAMPEDEing metastatic prostate cancer: CHAARTing the LATITUDEs. Indian J Urol. 2018; 34: 180-4

  7. Chi KN et al. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2019; 381: 13-24

  8. Davis ID et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019; 381: 121-31

  9. Patel GK et al. Neuroendocrine Differentiation of Prostate Cancer-An Intriguing Example of Tumor Evolution at Play. Cancers (Basel). 2019; 11: 1405

  10. Aparicio AM et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013; 19: 3621-30

  11. Epstein JI et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014; 38: 756-67

  12. Labrecque MP et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019; 129: 4492-505

  13. Tapia-Laliena, M.A., et al., High-risk prostate cancer: a disease of genomic instability. Urol Oncol. 2014; 32: 1101-7

  14. Nientiedt C et al. PARP inhibition in BRCA2-mutated prostate cancer. Ann Oncol. 2017; 28: 189-91

  15. Nientiedt C et al. Mutations in BRCA2 and taxane resistance in prostate cancer. Sci Rep. 2017; 7: 4574

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Urologie, Universitätsklinikum Carl Gustav Carus, Fetscherstraße 74, 01307, Dresden, Germany

    Holger H.H. Erb

  2. Klinik und Poliklinik für Urologie und Kinderurologie\nUniversitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Germany

    Christian Thomas

Authors
  1. Holger H.H. Erb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christian Thomas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Holger H.H. Erb.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Erb, H., Thomas, C. Notwendigkeit neuer Begrifflichkeiten . Uro-News 24, 10–13 (2020). https://doi.org/10.1007/s00092-020-4240-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00092-020-4240-4

Search

Navigation